US-based protein stabilisation technology developer Stablix Therapeutics launched yesterday with $63m in series A funding from investors including life science real estate investment trust Alexandria Real Estate Equities.

The round was led by venture capital firm Versant Ventures and included New Enterprise Associates, Cormorant Capital and Euclidean Capital while Alexandria Real Estate Equities took part through its Alexandria Venture Investments unit.

Stablix has developed targeted protein stabilisation technology that has applications in the treatment of rare diseases, cancer and immunological disorders. It is recruiting researchers for a laboratory facility in New York City and will use the capital to build out its platform and advance several candidates toward clinical trials.

Carlo Rizzuto, partner at Versant and acting chief executive of Stablix, said: “Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner.

“We are very pleased to launch this company to address this important therapeutic white space for numerous devastating diseases.”

The original version of this article appeared on our sister site, Global University Venturing.

Stablix Therapeutics, a US-based biotechnology company advancing research from Columbia University, launched yesterday with $63m in series A funding led by Versant Ventures.
The round also included Alexandria Venture Investments, the investment arm of life science real estate investment trust Alexandria Real Estate Equities, as well as New Enterprise Associates (NEA), Cormorant Capital and Euclidean Capital.
Stablix has developed targeted protein stabilisation technology that has applications in the treatment of rare diseases, cancer and immunological disorders.
The platform builds on work by Henry Colecraft, the John C Dalton professor of physiology and cellular biophysics at Columbia University. Colecraft’s co-founders include former PhD candidate Scott Kanner.
Carlo Rizzuto, partner at Versant and acting chief executive of Stablix, said: “Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner.
“We are very pleased to launch this company to address this important therapeutic white space for numerous devastating diseases.”
Stablix will use the series A capital to build out its platform and advance several candidates towards the clinic. The company has already opened a lab facility in New York City and is recruiting researchers.
Clare Ozawa, managing partner at Versant; Ali Behbahani, general partner at NEA; Kevin Sprott, co-founder and senior vice-president of drug discovery at Stablix; and Rizzuto make up the board of directors.
Andrew Phillips, managing director at Cormorant, and JC Lopez, principal at NEA, have joined the board as observers.